Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms
This study has been completed.
Sponsor:
Fred Hutchinson Cancer Research Center
Collaborators:
Information provided by:
Fred Hutchinson Cancer Research Center
ClinicalTrials.gov Identifier:
NCT01418209
First received: August 15, 2011
Last updated: May 20, 2013
Last verified: May 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary objective of this study is to determine the efficacy of both low-dose oral (by mouth) 17-ß-estradiol and the non-hormonal drug venlafaxine XR compared to placebo in reducing hot flashes. Included in this objective is the intention to compare venlafaxine XR to estradiol therapy, to provide evidence of the relative efficacy of venlafaxine to what is currently considered the most established but also a controversial therapy. 17-ß-estradiol is a type of estrogen. Venlafaxine XR is the extended release (XR) version of venlafaxine. Venlafaxine XR is an serotonin-norepinephrine reuptake inhibitor (SNRI). A placebo is a substance containing no medication.
| Condition | Intervention |
|---|---|
|
Hot Flashes Menopause Vasomotor Disturbance |
Drug: Low-dose 17-ß-estradiol Drug: Venlafaxine XR Drug: Placebo |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Comparative Efficacy of Low-Dose Estradiol and the SNRI Venlafaxine XR for Treatment of Menopausal Symptoms |
Resource links provided by NLM:
Drug Information available for:
Estradiol
Estradiol cypionate
Estradiol valerate
Estradiol acetate
Estradiol hemihydrate
Venlafaxine
Venlafaxine hydrochloride
U.S. FDA Resources
Further study details as provided by Fred Hutchinson Cancer Research Center:
Primary Outcome Measures:
- Frequency of hot flashes [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]Measured by self-report diary twice daily for 7 days
- Bothersomeness of hot flashes [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]Measured by self-report diary twice daily for 7 days.
- Severity of hot flashes [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]Measured by self-report diary twice daily for 7 days
Secondary Outcome Measures:
- Sleep disturbance [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]As measured by sleep diaries and possibly a sleep monitor wrist-device worn at home 7 days at the start and end of the study.
- Depression (depressive symptoms) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]Measured by self-report responses to questionnaire
- Anxiety [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]Measured by self-report responses to questionnaire
- Sexual function [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]Measured by self-report responses to questionnaire
| Estimated Enrollment: | 304 |
| Study Start Date: | November 2011 |
| Study Completion Date: | January 2013 |
| Primary Completion Date: | January 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Low-dose 17-ß-estradiol |
Drug: Low-dose 17-ß-estradiol
Low-dose 17-ß-estradiol oral (by mouth), 0.5 mg once per day for 8 (eight) weeks. After the 8-week treatment, women with a uterus will receive medroxyprogesterone 10 mg once per day for 2 weeks (14 days). 17-ß-estradiol is approved by the US Food and Drug Administration (FDA) and is indicated for the treatment of menopausal symptoms. ß is the Greek symbol for beta; the symbol and the word are used interchangeably.
Other Name: The brand name of estradiol being used in this study is Estrace®.
|
| Active Comparator: Venlafaxine XR |
Drug: Venlafaxine XR
Venlafaxine oral (by mouth) 37.5 mg once per day for 1 (one) week, then 75 mg once per day for 7 (seven) weeks. Venlafaxine XR should not be taken while also taking monoamine oxidase inhibitors (MAOIs). Venlafaxine XR is approved by the US Food and Drug Administration (FDA) for treatment of depression, generalized anxiety disorder, social anxiety disorder, and panic disorder, and is available by prescription. Venlafaxine XR is not FDA-approved for the treatment of hot flashes, although prior studies have indicated that it is useful for treating hot flashes and vasomotor symptoms. After the 8-week venlafaxine XR study treatment period, women will receive a tapering dose of venlafaxine XR 37.5 mg once per day for 14 days (2 weeks).
Other Name: The brand name of venlafaxine XR that is being used in this study is Effexor XR®
|
| Placebo Comparator: Placebo |
Drug: Placebo
The placebo is an inactive pill that looks like the active medication.
|
Detailed Description:
The MsFLASH-03 study, Comparative Efficacy of Low-Dose Estradiol and the SNRI Venlafaxine XR for Treatment of Menopausal Symptoms, is a randomized, double-blind, placebo-controlled, three arm clinical trial. The design includes: 3 weeks of daily recording of hot flashes prior to drug treatment; 8 weeks of double-blind treatment with oral estradiol, venlafaxine, or placebo; followed by 14 days of drug taper for those on venlafaxine and 14 days of progesterone treatment for those on estradiol; followed by 2 weeks with no treatment for all groups; and a telephone follow-up post-treatment.
Eligibility| Ages Eligible for Study: | 40 Years to 62 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Females aged 40-62 years
- Postmenopausal or perimenopausal
- Having bothersome hot flashes
- In general good health
- Signed informed consent
Exclusion Criteria:
- Recent use of systemic hormone therapy or hormonal contraceptives
- Recent use of any prescribed, over-the-counter or herbal therapies that are taken specifically for hot flashes
- Recent use of selective estrogen receptor modulators (SERMS) or aromatase inhibitors
- Recent use of psychotropic medications, including SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin-norepinephrine reuptake inhibitors), MAOIs (monoamine oxidase inhibitors), and other antidepressants and anxiolytics.
- Known hypersensitivity or contraindications (reasons not to take) to venlafaxine, estrogen, or progestins
- Not using a medically approved method of birth control, if sexually active and not 12 or more months since last menstrual period
- Recent drug or alcohol abuse
- Lifetime diagnosis of psychosis or bipolar disorder
- Suicide attempt in the past 3 years or any current suicidal ideation
- Current major depression (assessed during screening)
- Pregnancy, intending pregnancy, or breast feeding
History of:
- Pre-breast cancer or high-risk breast cancer condition
- Abnormal bleeding suggestive of endometrial pre-cancer or endometrial hyperplasia
- Asthma, diabetes mellitus, epilepsy, and migraine disorders that are not stable or under medical management
- Abnormal screening blood tests
- Current participation in another drug trial or intervention study
- Inability or unwillingness to complete the study procedures
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01418209
Locations
| United States, Massachusetts | |
| Massachusetts General Hospital, Harvard Medical School (HU) | |
| Boston, Massachusetts, United States, 02114 | |
| Brigham and Women's Hospital | |
| Chestnut Hill, Massachusetts, United States, 02215 | |
| United States, Pennsylvania | |
| University of Pennsylvania, UP | |
| Philadelphia, Pennsylvania, United States, 19104 | |
| United States, Washington | |
| Group Health Research Institute (GHRI) | |
| Seattle, Washington, United States, 98101 | |
Sponsors and Collaborators
Fred Hutchinson Cancer Research Center
Investigators
| Principal Investigator: | Andrea Z LaCroix, PhD | Fred Hutchinson Cancer Research Center |
| Principal Investigator: | Garnet Anderson, PhD | Fred Hutchinson Cancer Research Center |
| Principal Investigator: | Katherine Guthrie, PhD | Fred Hutchinson Cancer Research Center |
| Principal Investigator: | Lee S Cohen, MD | Massachusetts General Hospital/Harvard Medical School (HU) |
| Principal Investigator: | Hadine Joffe, MD, MSc | Massachusetts General Hospital/Harvard Medical School (HU) |
| Principal Investigator: | Katherine M Newton, PhD | Group Health Research Institute (GHRI) |
| Principal Investigator: | Susan D Reed, MD | University of Washington/Group Health Research Institute (GHRI) |
| Study Director: | Janet Carpenter, PhD, RN, FAAN | Indiana University School of Medicine |
| Principal Investigator: | Ellen W Freeman, PhD | University of Pennsylvania School of Medicine (UP) |
More Information
No publications provided
| Responsible Party: | Andrea LaCroix, Garnet Anderson, Fred Hutchinson Cancer Research Center |
| ClinicalTrials.gov Identifier: | NCT01418209 History of Changes |
| Other Study ID Numbers: | MsFLASH-03, 1U01AG032700-01, 1U01AG032699-01 |
| Study First Received: | August 15, 2011 |
| Last Updated: | May 20, 2013 |
| Health Authority: | United States: Federal Government |
Keywords provided by Fred Hutchinson Cancer Research Center:
|
Menopause Vasomotor Symptoms Estradiol Venlafaxine |
Additional relevant MeSH terms:
|
Hot Flashes Signs and Symptoms Estradiol Polyestradiol phosphate Estradiol valerate Estradiol 3-benzoate Estradiol 17 beta-cypionate Venlafaxine Estrogens Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Pharmacologic Actions |
Contraceptive Agents Reproductive Control Agents Therapeutic Uses Contraceptive Agents, Female Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Serotonin Agents Antidepressive Agents, Second-Generation Antidepressive Agents Psychotropic Drugs Central Nervous System Agents |
ClinicalTrials.gov processed this record on May 22, 2013